HE4、CA125及ROMA在卵巢肿瘤良恶性鉴别的临床应用价值  

Clinical Value of HE4,CA125 and ROMA in Differentiating Benign and Malignant Ovarian Masses

作　　者：王雅菲[1] 郭玉 王慧利 托娅[1] 王丽娟[1] 

机构地区：[1]内蒙古医科大学附属医院检验科,内蒙古呼和浩特100050 [2]内蒙古武川县医院检验科,内蒙古呼和浩特100050

出　　处：《标记免疫分析与临床》2017年第11期1216-1220,1279,共6页Labeled Immunoassays and Clinical Medicine

基　　金：2017年度内蒙古自治区科技计划项目

摘　　要：目的评估HE4、CA125和ROMA对卵巢癌的术前鉴别诊断价值。方法电化学发光法检测卵巢癌组(54例)和良性卵巢肿瘤组(103例)女性血清HE4和CA125浓度,根据患者绝经与否计算ROMA值。应用统计分析,对比绝经前后HE4、CA125和ROMA三项血清学指标的诊断性能。结果卵巢癌组较良性卵巢肿瘤块组患者血清HE4、CA125和ROMA值显著增高,差异有统计学意义(P<0.005)。所有患者HE4、CA125和ROMA的AUC分别是:0.962、0.899和0.963。三项血清学指标对绝经后妇女较绝经前妇女具有更高的灵敏度(分别为:HE4 91.4%vs 84.2%,CA125 97.1%vs84.0%和ROMA 91.4%vs 84.6%),血清HE4、CA125及ROMA绝经前后特异性分别为:92.9%vs 93.6%,87.5%vs83.0%,94.6%vs 95.7%。结论 HE4、ROMA在区分卵巢癌和良性卵巢肿瘤表现出较好的诊断性能。HE4和ROMA在鉴别女性卵巢癌和良性卵巢肿瘤特异性较高,CA125在绝经后卵巢癌患者有高灵敏度。Objective To evaluate the HE4, CA125 and ROMA in the differential diagnosis of ovarian carcinoma before operation. Methods Electrochemiluminescence was applied to detect serum HE4 and CA125 concentration in ovarian cancer group（ n = 54 ） and benign ovarian mass group（ n = 103 ）, according to the menopause status to calculate the value of ROMA, and compare the diagnostic performance of HE4, CA125 and ROMA in both pre-and post menopause patients. Results Serum levels of HE4, CA125 and values of ROMA were higher in patients with ovarian cancer than those with benign ovarian 1 mass, and the difference was statistically significant（ P 〈 0. 001 ）. The AUC for HE4, CA125 and ROMA in all patients were 0. 962, 0. 899 and 0. 963, respectively. Serum markers in postmenopausal women had higher sensitivity than those in premenopausal patient （HE4：91.4 vs 84.2% ,CA125： 97. 1 vs 84.0% and ROMA： 91.4 vs 84.6% , respectively）. Serum levels of HE4, CA125 and ROMA in pre-and postmenopause patients were 92.9 vs 93.6%, 87. 5 vs 83.0%, 94. 6 vs 95. 7%, respectively. Conclusion HE4 and ROMA shows the better diagnostic performance to distinguish epithelial ovarian cancer from benign ovarian mass. High specificity of HFA and ROMA is in differentiating benign ovarian mass from ovarian cancer, and CA125 has high sensitivity in postmenopausal women with ovarian cancer.

关 键 词：HE4 CA125 ROMA 卵巢癌 

分 类 号：R730.43[医药卫生—肿瘤] R737.31[医药卫生—临床医学]